Why Is TYRA BIOSCIENCES INC (TYRA) Stock Up Today?

TYRA stock is up 16.02% to $25.56 as of the latest trade, driven by the company’s announcement of a $400 million underwritten offering of common stock and pre-funded warrants. The offering, priced at $22.03 per share, is intended to fund the development of dabogratinib and other programs. The stock opened with a 1.9% gap up and has traded higher throughout the session, reaching a high of $25.65.

What Happened

Tyra Biosciences announced the pricing of a $400 million equity offering on September 14, 2026. The offering includes 9.079 million shares of common stock and an equal number of pre-funded warrants, priced at $22.03 per share. The proceeds will support the development of dabogratinib, a key program in the company’s pipeline. This move follows the company’s filing of an automatic shelf registration for securities offerings, which allows for flexibility in future capital raises. Cantor Fitzgerald recently reiterates its stock rating, adding to the positive backdrop for the company.

What The Data Shows

The stock opened at $22.45, a $22.03 close, and has since surged to $25.54. The session has seen 0.4 million shares traded, which is 0.5 times the 3-month daily average. The stock has printed 19 fresh 52-week highs on September 14, and has traded between $11.70 and $40.65 over the past 52 weeks. Over the last 8 sessions, the stock declined 5.8% from $25.13 to $23.66, making the current move a significant reversal. A director, Verjee Rehan, bought shares on September 9, and insiders have made one purchase totaling $20,000 in the last 90 days.

What To Watch

The company’s upcoming developments in dabogratinib will be key to monitor, as well as the performance of the newly issued shares. Retail traders are discussing the offering on social media, but no earnings date is scheduled in the near term. Coverage breadth and analyst commentary will be important to watch as the stock continues to trade near its 52-week high.